Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse급성 재발의 징후를 나타내는 다발성 경화증을 가진 리툭시맙으로 치료받은 사람에서 BBIBP-CorV COVID-19 백신 접종 후 항-NMDA 수용체 항체 검출Article Published on 2022-12-312022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] added administration Anti-N-methyl-D-aspartate receptor Anti-N-Methyl-d-Aspartate receptor antibodies anti-NMDAR antibodies antibody ataxic Autoimmune Autoimmune encephalitis Babinski sign BBIBP-CorV benefit Case report clinician corticosteroid pulse COVID-19 COVID-19 vaccination CSF analysis detection early diagnosis Encephalitis initiated manifestation MRI multiple sclerosis multiple sclerosis. Neurological symptom NMDAR Patient performed Physical examination plaques positive presenting receiving receptor second dose serum Sinopharm Symptoms tested therapy Vaccines worsening [DOI] 10.1080/21645515.2022.2033540 PMC 바로가기 [Article Type] Article
Knowledge and attitude toward the second round of COVID-19 vaccines among teachers working at southern public universities in EthiopiaArticle Published on 2022-12-312023-07-08 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), [키워드] Attitude COVID-19 vaccine knowledge second dose teachers. [DOI] 10.1080/21645515.2021.2018895 PMC 바로가기
COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach영국 웨일즈에서 50세 이상 성인의 COVID-19 백신 섭취 및 효과: 120만 인구 데이터 연결 코호트 접근법Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] 95%CI Adult affected Alpha approach BNT162b2 ChAdOx1 ChAdOx1 vaccine ChAdOx1 vaccines Characteristics Cohort collected data Coverage COVID-19 COVID-19 vaccine COVID-19 vaccines death Delta dose doses Effectiveness estimate first dose followed by Hospital admission immunization Infection linkage of BNT162b2 Older outcome outcomes PCR positive PCR positive SARS-CoV-2 infection post vaccination predominant SARS-CoV-2 SARS-COV-2 infection schedule second dose Seven strain vaccination vaccination. Vaccine variants Wales [DOI] 10.1080/21645515.2022.2031774 PMC 바로가기 [Article Type] Article
Global reports of takotsubo (stress) cardiomyopathy following COVID-19 vaccination: A systematic review and meta-analysisReview article Published on 2022-12-012022-10-05 Journal: IJC Heart & Vasculature [Category] 바이오마커, [키워드] addition age average BNT162b2 Broken heart syndrome Cardiomyopathy Case report ChAdOx1 nCoV-19 Complication concern conducted COVID-19 COVID-19 vaccinations COVID-19 vaccine COVID-19 vaccines ECG Ejection fraction elevated female first dose Google Scholar Hospital stay individual life-threatening LVEF male Messenger RNA Meta-analysis mRNA mRNA vaccine mRNA-1273 occurred onset of symptom Pain participated Patient patients raised receiving second dose Stress Stress cardiomyopathy Symptom Symptoms systematic literature search systematic review Takotsubo cardiomyopathy TCM the mean the patient troponin test vaccination Vaccines ventricular Web of Science with COVID-19 [DOI] 10.1016/j.ijcha.2022.101108 [Article Type] Review article
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant [DOI] 10.1002/jmv.28055 PMC 바로가기
Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in IranArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, [키워드] adenoviral-vectored vaccine Administered administration age anti-SARS-CoV-2 Anti-spike anti-spike antibody antibody Antibody Response average blood sample calculated center coronavirus disease Covaxin COVID-19 COVID-19 infection COVID-19 vaccine Cutoff ELISA evaluated Frequency healthcare worker individual Iran men Neutralizing antibodies neutralizing antibody neutralizing antibody. outcome Oxford/AstraZeneca pandemic participant participated positive proportion second dose significantly higher single center Sinopharm Sputnik V vaccination Vaccine Vaccines [DOI] 10.1002/jmv.28029 PMC 바로가기
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study단일 의료 시스템에서 의료 종사자들 사이에서 BNT162b2 백신 접종 후 SARS-CoV-2 스파이크 단백질에 대한 부작용과 면역 반응 사이의 연관성: 전향적 관찰 코호트 연구Observational Study Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, SARS, 임상, 진단, [키워드] administration Adverse Adverse reaction Anti-spike IgG antibody anti-spike IgG level Antibody titer association Asthma BNT162b2 BNT162b2 vaccine conducted COVID-19 Cutoff determine Factor first dose healthcare healthcare worker help humoral humoral immune response Humoral response IgG IgG level immune response information Local majority median median age mRNA mRNA vaccine of BNT162b2 participant Participants prospective observational cohort reaction recipients recruited reported SARS-CoV-2 anti-spike IgG SARS-CoV-2 spike protein second dose significantly higher systemic adverse reactions Systemic adverse reactions. systemic reaction vaccination Vaccine was collected were measured with COVID-19 women [DOI] 10.1080/21645515.2022.2048559 PMC 바로가기 [Article Type] Observational Study
Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variantsArticle Published on 2022-11-082022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] analysed B.1 B.1.617.2 BBIBP-CorV booster vaccination ChAdOx1-S Combination country COVID-19 elicited exhibited Gam-COVID-Vac greater Heterologous heterologous vaccination homologous immunized information mRNA-1273 mRNA-1273 vaccines Neutralizing Neutralizing antibodies non-replicative P.1 participant percentage Population protocol protocols provided SARS-CoV-2 second dose serum shortage significantly significantly lower vaccination Vaccination strategies Vaccination strategy Vaccine variant variants of concern. viral vector-based [DOI] 10.1016/j.vaccine.2022.10.021 PMC 바로가기